<?xml version="1.0" encoding="UTF-8"?>

<Composition xmlns="http://hl7.org/fhir">
  <id value="composition25bbfa948f4a0b224f9baa1fe481efa8"/>
  <meta>
    <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><p><b>Generated Narrative: Composition</b><a name="composition25bbfa948f4a0b224f9baa1fe481efa8"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Composition &quot;composition25bbfa948f4a0b224f9baa1fe481efa8&quot;  (Language &quot;en&quot;) </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: id:Â 50d2abb4441275478b3d10432498aec6</p><p><b>status</b>: final</p><p><b>type</b>: Package Leaflet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#100000155538)</span></p><p><b>category</b>: Raw <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-epicategory-cs.html">Category of EPI</a>#R)</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-9800de324c3962f6f767647a95e0c17e.html">Organization/mah-9800de324c3962f6f767647a95e0c17e</a> &quot;Pfizer Europe MA EEIG&quot;</p><p><b>title</b>: TEST PURPOSES ONLY - Enbrel 25 mg powder for solution for injection</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td>Official <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-composition-attestation-mode.html">Composition Attestation Mode</a>#official)</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
  </text>
  <identifier>
    <system value="https://spor.ema.europa.eu/rmswi/"/>
    <value value="50d2abb4441275478b3d10432498aec6"/>
  </identifier>
  <status value="final"/>
  <type>
    <coding>
      <system value="https://spor.ema.europa.eu/rmswi/"/>
      <code value="100000155538"/>
    </coding>
    <text value="Package Leaflet"/>
  </type>
  <category>
    <coding>
      <system value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
      <code value="R"/>
      <display value="Raw"/>
    </coding>
  </category>
  <subject>
    <reference value="MedicinalProductDefinition/mp25bbfa948f4a0b224f9baa1fe481efa8"/>
  </subject>
  <date value="2022-02-16T13:28:17Z"/>
  <author>
    <reference value="Organization/mah-9800de324c3962f6f767647a95e0c17e"/>
  </author>
  <title value="TEST PURPOSES ONLY - Enbrel 25 mg powder for solution for injection"/>
  <attester>
    <mode>
      <coding>
        <system value="http://hl7.org/fhir/composition-attestation-mode"/>
        <code value="official"/>
      </coding>
    </mode>
    <time value="2022-02-16T13:28:17Z"/>
  </attester>
  <section>
    <title value="A. SUMMARY OF PRODUCT CHARACTERISTICS"/>
    <code>
      <coding>
        <system value="https://spor.ema.europa.eu/rmswi/"/>
        <code value="100000155538"/>
      </coding>
      <text value="A. SUMMARY OF PRODUCT CHARACTERISTICS"/>
    </code>
    <text>
      <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
    </text>
    <emptyReason>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
        <code value="unavailable"/>
      </coding>
    </emptyReason>
    <section>
      <title value="1. NAME OF THE MEDICINAL PRODUCT"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="1. NAME OF THE MEDICINAL PRODUCT"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">Enbrel 25 mg powder for solution for injection</div>
      </text>
    </section>
    <section>
      <title value="2. QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="2. QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p>Each vial contains 25 mg of etanercept.</p><p>Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.</p><p>For the full list of excipients, see section 6.1.</p></div>
      </text>
    </section>
    <section>
      <title value="3. PHARMACEUTICAL FORM"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="3. PHARMACEUTICAL FORM"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p>Powder for solution for injection (powder for injection).</p><p>The powder is white.</p></div>
      </text>
    </section>
    <section>
      <title value="4. CLINICAL PARTICULARS"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="4. CLINICAL PARTICULARS"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
      <section>
        <title value="4.1 Therapeutic indications"/>
        <code>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi/"/>
            <code value="100000155538"/>
          </coding>
          <text value="4.1 Therapeutic indications"/>
        </code>
        <text>
          <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p><strong>Rheumatoid arthritis</strong></p><p>Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.</p><p><strong>Juvenile idiopathic arthritis</strong></p><p>Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.</p><p><strong>Psoriatic arthritis</strong></p><p>Treatment of active and progressive psoriatic arthritis in adults when the response to previous diseasemodifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.</p><p><strong>Axial spondyloarthritis</strong></p><p><em>Ankylosing spondylitis (AS)</em></p><p>Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</p><p><em>Non-radiographic axial spondyloarthritis</em></p><p>Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p><strong>Plaque psoriasis</strong></p><p>Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) (see section 5.1).</p><p><strong>Paediatric plaque psoriasis</strong></p><p>Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p></div>
        </text>
      </section>
    </section>
  </section>
  <section>
    <title value="B. Package Leaflet"/>
    <code>
      <coding>
        <system value="https://spor.ema.europa.eu/rmswi/"/>
        <code value="100000155538"/>
      </coding>
      <text value="B. PACKAGE LEAFLET"/>
    </code>
    <text>
      <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
    </text>
    <emptyReason>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
        <code value="unavailable"/>
      </coding>
    </emptyReason>
    <section>
      <title value="Package leaflet: Information for the user"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="Package leaflet: Information for the user"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
    <section>
      <title value="What is in this leaflet"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="What is in this leaflet"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
    <section>
      <title value="1. What Enbrel 25 mg powder for solution for injection is and what it is used for"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="1. What Enbrel 25 mg powder for solution for injection is and what it is used for"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
    <section>
      <title value="2. What you need to know before you take Enbrel 25 mg powder for solution for injection"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="2. What you need to know before you take Enbrel 25 mg powder for solution for injection"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
    <section>
      <title value="3. How to take Enbrel 25 mg powder for solution for injection"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="3. How to take Enbrel 25 mg powder for solution for injection"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
    <section>
      <title value="4. Possible side effects"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="4. Possible side effects"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
    <section>
      <title value="5. How to store Enbrel 25 mg powder for solution for injection"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="5. How to store Enbrel 25 mg powder for solution for injection"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
    <section>
      <title value="6. Contents of the pack and other information"/>
      <code>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="100000155538"/>
        </coding>
        <text value="6. Contents of the pack and other information"/>
      </code>
      <text>
        <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
      </text>
      <emptyReason>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
          <code value="unavailable"/>
        </coding>
      </emptyReason>
    </section>
  </section>
</Composition>